Fulcrum Therapeutics (FULC) Consolidated Net Income (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Consolidated Net Income data on file, last reported at -$50.0 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 69.8% year-over-year to -$50.0 million in Q1 2026; TTM through Mar 2026 was -$241.1 million, a 179.3% decrease from a year earlier, with the FY2025 full-year figure at -$161.2 million, down 119.71% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$50.0 million, up from -$84.2 million in the prior quarter.
• Over the last five years, Consolidated Net Income for FULC reached as high as $40.2 million in Q2 2024 and fell as low as -$192.5 million in Q4 2022.
• Historically, Consolidated Net Income has averaged -$52.1 million across 5 years, with a median of -$42.0 million in 2025.
• Across the five-year window, Consolidated Net Income sank 310.77% in 2022 and soared 231.2% in 2024, its largest moves.
• Year by year, Consolidated Net Income stood at -$192.5 million in 2022, then surged by 77.6% to -$43.1 million in 2023, then tumbled by 65.71% to -$71.4 million in 2024, then declined by 17.81% to -$84.2 million in 2025, then jumped by 40.62% to -$50.0 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$50.0 million in Q1 2026, -$84.2 million in Q4 2025, and -$65.0 million in Q3 2025.